Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Fargo, ND
NPI: 1043426034Primary Practice Location
SANFORD MEDICAL CENTER FARGO
801 Broadway N, Fargo, ND
Primary Employer
Sanford Medical Center - Cavalier
sanfordhealth.org
Looking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNE State Medical License
ND State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 167 | 215 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 128 | 251 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 47 | 88 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 27 | 27 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 22 | 22 |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Authors: Vassiliki Papadimitrakopoulou, Amita Patnaik, Ryan Gentzler, Lecia Sequist, Steven Powell, Shirish Gadgeel, Shadia Jalal
Publication Date: 2016-09-30
Authors: Corey Langer, Mark Awad, Hossein Borghaei, Amita Patnaik, Ryan Gentzler, Lecia Sequist, Matthew Gubens, Steven Powell, Shirish Gadgeel, Shadia Jalal, Mehmet Altan
Journal: J Thorac Oncol
Publication Date: 2020-10-15
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Authors: Vassiliki Papadimitrakopoulou, Corey Langer, Amita Patnaik, Ryan Gentzler, Lecia Sequist, Steven Powell, Shirish Gadgeel, Shadia Jalal
Publication Date: 2018-04-27
Lead Sponsor: Washington University School of Medicine
Collaborators: Celgene Corporation
Intervention / Treatment: DRUG: Carboplatin, BIOLOGICAL: Cetuximab, DRUG: Cisplatin, DRUG: nab-paclitaxel
Lead Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, DRUG: Placebo Administration, DRUG: Rose Geranium in Sesame Oil Nasal Spray
Lead Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, DRUG: Gemcitabine Hydrochloride, DRUG: Chemotherapy, DRUG: Disulfiram
